Final results from M72 AS01E TB Vaccine Trial
The final results from the M72AS01E TB vaccine study have been published in the New England Journal of Medicine. The vaccine demonstrated a 50% efficacy rate in the incidence of lung TB disease in HIV-negative adults, already infected with latent...
Community Engagement
Carina's Choice: SATVI collaborated with UCT Drama Department and Worcester Secondary School in developing this play which was performed by learners from Worcester Secondary School at 8 local high schools reaching approximately 8 000 adolescents in...
Phase 3 efficacy study finds shortened 4-month TB drug therapy treatment equivalent to 6-months therapy
The New England Journal of Medicine has published the results of a clinical study which shows that in a randomised phase 3 clinical trial, a shortened 4-month TB treatment was equivalent to the standard 6-month TB treatment.
2020 Annual Report
The SATVI 2020 Annual Report is available for download.
New multi-functional TB blood test validated
Researchers the South African Tuberculosis Vaccine Initiative (SATVI), the Center for Global Infectious Disease Research(USA) and a large consortium of collaborators have developed a validated a new, simple blood-based test that has the potential to...


Sunday, 28 November 2021
4 February 2021 Opinion piece: How we know vaccines are safe and effective

Associate Professor Elisa Nemes, Dr Michele Tameris, Dr Virginie Rozot, Professor Thomas Scriba, and Dr Benjamin Kagina have written an opinion piece in which they explain the process vaccines and drugs have to go through before they can be approved for human use. This article appeared in the Health 24.

Publication Date:
Fri, 05 Feb 2021 - 21:30
25 January 2021 A blood biomarker of tuberculosis discriminated between people at high risk for tuberculosis and those who remained healthy, but an effective preventive therapy for people at risk remains elusive.

The Lancet Infectious Diseases journal reports the findings of a study of a host blood signature of TB that differentiated between people who had or would develop active TB and those who remained healthy, and investigated in parallel the effect of giving TB preventive therapy based on a positive signature result.

Publication Date:
Tue, 26 Jan 2021 - 10:00
8 January 2020 Opinion Piece: Why I choose COVID-19 vaccination based on verifiable evidence

Professor Tom Scriba has written an opinion piece for News24 in which he explains the safety profile of the 3 available COVID-19 vaccines & the benefits of receiving it.

Publication Date:
Fri, 08 Jan 2021 - 14:15
4 January 2020 News: SATVI researcher awarded full IDM membership

Associate Professor Elisa Nemes has been appointed full member of the Institute of Infectious Disease and Molecular Medicine at the UCT Health Sciences Faculty.

Publication Date:
Wed, 06 Jan 2021 - 09:00